Vas Narasimhan has been operating for a year: the 42-year-old American is quickly reorganizing the group. Meeting in Basel.
On 1 February 2018, Vas Narasimhan moved to his headquarters in Basel at the premises of a pharmaceutical company. By: It turned out to be a noble office with a prestige. Instead, he decided to continue working with others in the office with an open plan.
In this way, Narasimhan clearly stated that on the first working day he was at work as a boss: Novartis should change a lot. In his opinion, it does. The only 42-year-old business leader says corporate culture has improved significantly: Employees are "entrepreneurial", independent of the road. It calls a new corporate culture "without boss" – without a "boss".
Focus on high-tech drugs
Corporate culture is one thing. Company structure second. American Indian roots progress at a rapid pace. It calculates that last year, Novartis bought or sold $ 50 billion in the company.
"Everything Novartis is more focused on a high-tech drug company," says Narasimhan. For example, he bought a company worth nearly $ 9 billion to develop gene therapy, an individual treatment for serious illnesses. Such immunotherapy is promising and may soon revolutionize the treatment of cancer and other diseases.
In return, Narasimhan sells his business with simple, non-prescription drugs. And Alcon – daughter, eye manufacturers – will soon be separated as an independent company.
Big goal of pharmaceutical director: Novartis should be more profitable. It also moves the entire department to other countries and reduces the number of jobs – more than 2000 in Switzerland. As a result, the workforce shakes rather confusedly.
Significantly lower wages than its predecessors
These are the great plans pursued by the dynamic CEO. At the same time, he lets himself go: he usually leaves a tie in the closet at home, a classic dark suit. Even in the fact that – as it is today in business people's presentation – it focuses on the media.
We have a lot of plans. Now we have to produce results every year.
Narasimhan gains much less than his predecessors. He seems relaxed, accessible and yet determined. He says, "We have a lot of plans, and we also have to produce results every year."
Lift the sleeves
But research on high-tech drugs is prone to risk. And in the most important market – in the United States – there is also an excited debate about high drug prices. Fast prices that Novartis can publish last year.
And according to Narasimhan, they are likely to continue this year. His strategy: "In 2019, our sleeves developed and we did what we started in 2018." He says – well, he realizes that shareholders will not judge him with his promises, but with his results.